Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule

Kelowna, British Columbia — June 25, 2026 — Leads & Copy — Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7). The study is evaluating two oral DehydraTECH-semglutide (DHT-sema) compositions against Novo Nordisk’s® ("Novo") Wegovy® tablets over a five-week period. This research aims to assess safety, tolerability, and pharmacokinetic performance in comparison to established commercial products.

Lexaria, listed on Nasdaq under the ticker symbol LEXX, is developing novel drug delivery technologies through its proprietary DehydraTECH™ platform, which enhances drug absorption and delivery. The current study—funded from the company's existing resources—seeks to build on previous research that demonstrated promising safety profiles and PK performance matching or exceeding that of Wegovy® and Rybelsus® controls.

The study is structured into three arms, comparing SNAC-inclusive, DHT-sema formulations in tablet and capsule formats to Wegovy® tablets. Conducted under fasted pre-dose conditions similar to those for Novo’s oral semaglutide, the study’s five-week duration allows for achieving steady-state drug levels, providing a reliable basis for assessing absorption and safety over a longer-term administration.

Innovations in this study include the use of an oral tablet DHT-sema composition for the first time, replicating properties of industry-standard Semaglutide tablet delivery systems like Rybelsus® and Wegovy®, which adhere to the stomach lining and dissolve to optimize absorption. The formulations also incorporate sodium salcaprozate (SNAC), evaluated over a multi-week, multi-dose period—marking a significant advancement from earlier single-dose studies conducted in 2024 and 2025.

Lexaria’s DehydraTECH™ platform aims to improve drug absorption, reduce side effects, and facilitate effective crossing of the blood-brain barrier for various drugs. The company holds 66 patents globally, with more pending, and operates a research lab focused on advanced drug delivery technologies. The new study’s outcomes are anticipated to influence future pharmaceutical collaborations and commercial applications.

The company emphasized that the results of this study will be carefully reviewed by the pharmaceutical industry, with the goal of progressing toward potential commercial relationships based on DehydraTECH™ technology. The study's innovative approach—particularly the inclusion of SNAC in multi-week dosing and the testing of tablet formulations—represents a significant development in oral peptide delivery.

For more information, please visit www.lexariabioscience.com.

Source: Lexaria Bioscience Corp.